Please visit answersincme.com/860/101393625-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Yohann Loriot, MD, PhD and Andrea Necchi, MD. In this activity, experts in genitourinary cancers examine evidence-based strategies for integrating HER2 biomarker testing and HER2-directed antibody-drug conjugates into personalized, multidisciplinary care for advanced bladder cancer. Upon completion of this activity, participants should be better able to: Apply current guidelines to incorporate biomarker testing into treatment pathways for advanced bladder cancer; Evaluate emerging data on HER2-directed antibody-drug conjugates to guide the management of advanced bladder cancer; and Formulate multidisciplinary treatment plans to support personalized care for patients with HER2-positive advanced bladder cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related